Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 10
mi
from
Jacksonville, FL
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 10
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 8
mi
from
Miami Springs, FL
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 8
mi
from
Miami Springs, FL
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 6
mi
from
Orlando, FL
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 6
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 17
mi
from
Tampa, FL
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 17
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 12
mi
from
Kansas City, KA
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 12
mi
from
Kansas City, KA
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 21
mi
from
Lenexa, KA
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 21
mi
from
Lenexa, KA
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 1
mi
from
Bingham Farms, MI
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 1
mi
from
Bingham Farms, MI
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 10
mi
from
Charlotte, NC
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 10
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 9
mi
from
Cleveland, OH
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 9
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 61
mi
from
Richland, WA
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 61
mi
from
Richland, WA
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 18
mi
from
Moscow,
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 18
mi
from
Moscow,
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 11
mi
from
Miami, FL
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 11
mi
from
Miami, FL
Click here to add this to my saved trials
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated:  12/31/1969
SPARC Site 36
mi
from
Albuquerque, NM
Study of SPARC1103 in Subjects With Spasticity
Status: Enrolling
Updated: 12/31/1969
SPARC Site 36
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Pediatric Epilepsy Center Of Central Florida
mi
from
Orlando, FL
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Pediatric Epilepsy Center Of Central Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Pediatric Neurology, PA
mi
from
Orlando, FL
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Pediatric Neurology, PA
mi
from
Orlando, FL
Click here to add this to my saved trials
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Pediatric Epilepsy and Neurology Specialists
mi
from
Tampa, FL
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Pediatric Epilepsy and Neurology Specialists
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
Road Runner Research
mi
from
San Antonio, TX
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
Road Runner Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated:  12/31/1969
GU Republican Scientific and Practical Center Mother and Child
mi
from
Minsk,
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures
Status: Enrolling
Updated: 12/31/1969
GU Republican Scientific and Practical Center Mother and Child
mi
from
Minsk,
Click here to add this to my saved trials
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sheffield, AL
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sheffield, AL
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Smith, AR
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Anaheim, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Beverly Hills, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fullerton, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Newport Beach, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orange, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Marino, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Marino, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Ana, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Colorado Springs, CO
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bridgeport, CT
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Danbury, CT
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Danbury, CT
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New Haven, CT
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Waterbury, CT
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlantis, FL
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlantis, FL
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bay Pines, FL
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bay Pines, FL
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bradenton, FL
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Brandon, FL
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Brandon, FL
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Celebration, FL
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Celebration, FL
Click here to add this to my saved trials